All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

MEDI9253 Plus Durvalumab Delivers Little Efficacy in Advanced/Metastatic Solid Tumors

March 22nd 2023

The addition of MEDI9253 to sequential or concurrent treatment with durvalumab failed to elicit more than 1 partial response although proving feasible and safe in patients with advanced or metastatic solid tumors, according to findings from a phase 1 trial.

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

A new drug application seeking the approval of Lumisight, an optical imaging agent that detects cancerous tissue during initial lumpectomy to allow for a more complete resection, has been submitted to the FDA.

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Axicabtagene ciloleucel produced a statistically significant improvement in overall survival compared with standard-of-caretherapy in patients with relapsed/refractory large B-cell lymphoma, according to data from the ZUMA-7 trial.

Adjuvant Pembrolizumab Expands Options for Patients with Resected Stage IB-IIIA NSCLC

March 21st 2023

Luis Paz-Ares, MD, PhD, highlight adverse events to monitor with pembrolizumab in this setting as well as its role in the treatment landscape.

Thomas K. Varghese Jr. MD, MS, MBA, FACS, Named President-Elect of Society of University Surgeons

March 21st 2023

Varghese, known for his innovative research in perioperative care and mentorship to physician-scientists, will become SUS President in February 2024.

FDA Grants Orphan Drug Designation to ISB 1442 for Relapsed/Refractory Multiple Myeloma

March 21st 2023

The FDA has granted an orphan drug designation to ISB 1442, the first-in-class biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47 for the treatment of patients with relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to FORE8394 for Primary Brain and CNS Malignancies

March 21st 2023

The FDA has granted an orphan drug designation to FORE8394 for the treatment of primary brain and central nervous system malignancies.

HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain

March 21st 2023

Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.

Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FL

March 21st 2023

A real-world analysis exploring the outcomes of inpatient vs outpatient administration of CAR T-cell therapy in patients with mantle cell lymphoma and follicular lymphoma demonstrated both similarities and some differences between the 2 patient populations.

VTP-200 Elicits Immunogenic Responses, Tolerability in HPV+ Cervical Lesions

March 20th 2023

VTP-200 generated immunogenic responses and tolerability in patients with human papillomavirus–positive cervical lesions.

Allocetra Plus Chemotherapy Receives Green Light to Continue Investigation in Solid Tumors With Peritoneal Metastasis

March 20th 2023

The phase 1/2 trial evaluating the addition of Allocetra to standard chemotherapy administered via pressurized intraperitoneal aerosol chemotherapy received regulatory clearance to continue evaluation and launch the dose-escalation cohort in patients with advanced-stage peritoneal metastasis arising from solid tumors following the completion of an interim data review by an Independent Data and Safety Monitoring Board and the Israeli Ministry of Health.

Dostarlimab Fills Unmet Need for Patients with dMMR Advanced Endometrial Cancer

March 20th 2023

Lucy Gilbert, MD, MSc, discusses the favorable safety profile of dostarlimab as well as how it compares with the current standard of care in mismatch repair deficient advanced endometrial cancer.

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Patritumab deruxtecan elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer and patients with HER3-expressing metastatic breast cancer.

First-line ASCT Consolidation Confers Real-world Survival Benefit in Mantle Cell Lymphoma

March 20th 2023

Consolidative autologous stem cell transplant was associated with a statistically significant lower overall mortality risk and higher overall survival probability in patients with mantle cell lymphoma vs those who did not receive consolidation.

Cancer Center Leader Appointed to Establish Inaugural Office

March 20th 2023

Jennifer Hatcher, PhD, RN, MPH, has been appointed as associate director of Inclusivity, Diversity, Equity and Accessibility for the University of Arizona Cancer Center.

Integrating New Standards for Metastatic HER2+ Breast Cancer

March 20th 2023

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.

Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer

March 20th 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Eunice Wang, MD, discusses the current standards for classifying and treating unfit patients with AML, treatment considerations for patients unfit for hypomethylating agents, and the potential role of investigational menin inhibitors and immunotherapies in this population.

JTX-8064 Plus Pimivalimab Elicits Durable Responses in Platinum-Resistant Ovarian Cancer

March 17th 2023

The combination of JTX-8064 and pimivalimab generated deep and durable responses in patients with third- or fourth-line platinum-resistant ovarian cancer.